Scarica l'app Stockscreener
25.39
0.21%
0.0524
Xoma Corporation Borsa (XOMAO) Ultime notizie
XOMA Royalty Declares Quarterly Preferred Stock Dividends - GlobeNewswire
XOMA Preferred Stock Pays High-Yield Quarterly Dividend: 8.625% Series A, 8.375% Series B - Stock Titan
How the (XOMAO) price action is used to our Advantage - news.stocktradersdaily.com
Learn to Evaluate (XOMA) using the Charts - news.stocktradersdaily.com
Bank of America Corp DE Acquires 2,009 Shares of XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMA) Rating Increased to Buy at Wall Street Zen - Defense World
Trading (XOMAP) With Integrated Risk Controls - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMA) Shares Sold by Squarepoint Ops LLC - Defense World
Nuveen Asset Management LLC Increases Stock Position in XOMA Co. (NASDAQ:XOMA) - Defense World
Long Term Trading Analysis for (XOMA) - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMA) Shares Sold by BNP Paribas Financial Markets - Defense World
BioInvent secured up to 30 MUSD from XOMA royalty - Biostock
BioStock: BioInvent secured up to 30 MUSD from XOMA royalty - TradingView
Wall Street Zen Upgrades XOMA (NASDAQ:XOMA) to Buy - Defense World
XOMA Royalty purchases mezagitamab royalty rights from BioInvent International for $30M - MSN
HC Wainwright Issues Positive Outlook for XOMA Earnings - Defense World
(XOMAP) Trading Report - news.stocktradersdaily.com
XOMA Co. (NASDAQ:XOMAO) Short Interest Update - Defense World
XOMA stock holds Buy rating, $104 target from H.C. Wainwright By Investing.com - Investing.com Canada
XOMA stock holds Buy rating, $104 target from H.C. Wainwright - Investing.com Australia
XOMA Co. (NASDAQ:XOMAP) Short Interest Update - Defense World
XOMA’s (XOMA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
XOMA Stock: HC Wainwright & Co. Reiterates Buy Rating with $104 - GuruFocus
XOMA Purchases Future Mezagitamab Royalty Interests from BioInve - GuruFocus
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent - marketscreener.com
XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInvent - GuruFocus
XOMA Royalty (XOMA) Acquires Mezagitamab Interests from BioInven - GuruFocus
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million - The Manila Times
XOMA Royalty Purchases Mezagitamab Royalty and Milestone - GlobeNewswire
(XOMAO) Technical Pivots with Risk Controls - news.stocktradersdaily.com
(XOMA) Trading Advice - news.stocktradersdaily.com
Northern Trust Corp Has $2.40 Million Holdings in XOMA Co. (NASDAQ:XOMA) - Defense World
XOMA (NASDAQ:XOMAO) Stock Price Up 0.1% – Still a Buy? - Defense World
XOMA (NASDAQ:XOMAP) Trading Up 1.5% – Still a Buy? - Defense World
Major Shareholder Sells Massive Chunk of Xoma Stock! - TipRanks
(XOMAP) Investment Report - news.stocktradersdaily.com
Leerink Partnrs Analysts Boost Earnings Estimates for XOMA - Defense World
FY2026 Earnings Estimate for XOMA Issued By Leerink Partnrs - Defense World
Results: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
(XOMA) Investment Analysis and Advice - news.stocktradersdaily.com
XOMA Royalty First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
XOMA Royalty Reports Strong Q1 2025 Results - TipRanks
XOMA Royalty Corp Q1 2025 Earnings: EPS of $0.24, Revenue Surges to $15.9 Million, Exceeding Estimates - GuruFocus
XOMA Royalty: Q1 Earnings Snapshot - New Haven Register
XOMA (XOMA) Surpasses Q1 Revenue Expectations with Strong Pipeli - GuruFocus
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
XOMA earnings beat by $0.35, revenue topped estimates - Investing.com
XOMA Royalty Corporation Q1 2025 Financial Results - TradingView
XOMA Royalty Corp SEC 10-Q Report - TradingView
0.78%
1.26%
Capitalizzazione:
|
Volume (24 ore):